Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert E Ratner

Showing results (41-50 of 87) with videos related to

Pageof 9
Sort By:
Diabetes Technology & Therapeutics|January 12, 2013
Cross-sectional evaluation of noninvasively detected skin intrinsic fluorescence and mean hemoglobin a1c in type 1 diabetesVanita R Aroda, Baqiyyah N Conway, Stephen J Fernandez, et al.
Diabetes Technology & Therapeutics|May 23, 2002
Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetesRobert E Ratner, Laura L Want, Mark S Fineman, et al.
The Journal of Clinical Endocrinology and Metabolism|October 2, 2008
Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventionsRobert E Ratner, Costas A Christophi, Boyd E Metzger, et al.
Diabetes Care|December 28, 2002
Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention programWilliam H Hernan, Michael Brandle, Ping Zhang, et al.
Diabetes Care|May 16, 2020
COVID-19 in People With Diabetes: Urgently Needed Lessons From Early ReportsMatthew C Riddle, John B Buse, Paul W Franks, et al.
The Journal of Clinical Psychiatry|April 11, 2009
A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidoneJohn W Newcomer, Robert E Ratner, Jan W Eriksson, et al.
Diabetes Care|August 19, 2007
Cost-effectiveness of screening for pre-diabetes among overweight and obese U.S. adultsThomas J Hoerger, Katherine A Hicks, Stephen W Sorensen, et al.
Diabetes Care|May 30, 2006
An evaluation of cost sharing to finance a diet and physical activity intervention to prevent diabetesRonald T Ackermann, David G Marrero, Katherine A Hicks, et al.
Diabetes Care|June 22, 2013
Scientific statement: Socioecological determinants of prediabetes and type 2 diabetesJames O Hill, James M Galloway, April Goley, et al.
Annals of Internal Medicine|March 2, 2005
The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose toleranceWilliam H Herman, Thomas J Hoerger, Michael Brandle, et al.
Pageof 9

Showing results (41-50 of 87) with videos related to

Sort By:
Pageof 9
Diabetes Technology & Therapeutics|January 12, 2013
Cross-sectional evaluation of noninvasively detected skin intrinsic fluorescence and mean hemoglobin a1c in type 1 diabetesVanita R Aroda, Baqiyyah N Conway, Stephen J Fernandez, et al.
Diabetes Technology & Therapeutics|May 23, 2002
Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetesRobert E Ratner, Laura L Want, Mark S Fineman, et al.
The Journal of Clinical Endocrinology and Metabolism|October 2, 2008
Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventionsRobert E Ratner, Costas A Christophi, Boyd E Metzger, et al.
Diabetes Care|December 28, 2002
Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention programWilliam H Hernan, Michael Brandle, Ping Zhang, et al.
Diabetes Care|May 16, 2020
COVID-19 in People With Diabetes: Urgently Needed Lessons From Early ReportsMatthew C Riddle, John B Buse, Paul W Franks, et al.
The Journal of Clinical Psychiatry|April 11, 2009
A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidoneJohn W Newcomer, Robert E Ratner, Jan W Eriksson, et al.
Diabetes Care|August 19, 2007
Cost-effectiveness of screening for pre-diabetes among overweight and obese U.S. adultsThomas J Hoerger, Katherine A Hicks, Stephen W Sorensen, et al.
Diabetes Care|May 30, 2006
An evaluation of cost sharing to finance a diet and physical activity intervention to prevent diabetesRonald T Ackermann, David G Marrero, Katherine A Hicks, et al.
Diabetes Care|June 22, 2013
Scientific statement: Socioecological determinants of prediabetes and type 2 diabetesJames O Hill, James M Galloway, April Goley, et al.
Annals of Internal Medicine|March 2, 2005
The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose toleranceWilliam H Herman, Thomas J Hoerger, Michael Brandle, et al.
Pageof 9